Payment overview · 2025
General Payments
$1,546.49
57 reported records · 19 companies
Healthcare provider profile · identity verified
Danka K Michaels, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAS VEGAS, NV · NPI 1730151044
Verified facts
What the public records show
CMS Open Payments records show Danka K Michaels, MD received $1,546.49 in general payments during 2025 across 57 reported records.
ABBVIE INC. accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $358.94 | 23.2% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $273.81 | 17.7% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $159.90 | 10.3% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $102.86 | 6.7% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $90.61 | 5.9% | 4 | 2025 |
| MERZ NORTH AMERICA, INC. | Unresolved — no canonical attribution shown | $76.73 | 5.0% | 3 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $71.43 | 4.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $61.60 | 4.0% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $43.99 | 2.8% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $42.48 | 2.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.33 | 2.7% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $38.52 | 2.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $38.24 | 2.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.64 | 2.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $29.22 | 1.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.75 | 1.6% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $21.51 | 1.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.43 | 1.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.50 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,256.39 | 53 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $290.10 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $159.90 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $156.91 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $102.86 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $102.70 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $90.61 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $90.61 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $71.96 | 2 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $71.43 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | MERZ NORTH AMERICA, INC. | $54.04 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $43.99 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $38.52 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $38.24 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.60 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.60 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $36.19 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.19 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.65 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $29.22 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 74 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 100 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
87 | 23 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
100 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
100 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
204 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
81 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 741 | 236 |
| Levothyroxine Sodium | Levothyroxine Sodium | 573 | 162 |
| Atorvastatin Calcium | Atorvastatin Calcium | 455 | 152 |
| Amlodipine Besylate | Amlodipine Besylate | 415 | 128 |
| Lisinopril | Lisinopril | 387 | 118 |
| Losartan Potassium | Losartan Potassium | 320 | 93 |
| Metformin Hcl | Metformin Hcl | 301 | 90 |
| Alprazolam | Alprazolam | 226 | 55 |
| Montelukast Sodium | Montelukast Sodium | 208 | 66 |
| Ozempic | Semaglutide | 204 | 37 |
| Omeprazole | Omeprazole | 191 | 61 |
| Simvastatin | Simvastatin | 162 | 50 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 150 | 91 |
| Gabapentin | Gabapentin | 149 | 47 |
| Allopurinol | Allopurinol | 145 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 129 | 39 |
| Trazodone Hcl | Trazodone Hcl | 125 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 116 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 22 |
| Jardiance | Empagliflozin | 100 | 29 |
| Sertraline Hcl | Sertraline Hcl | 98 | 29 |
| Ipratropium Bromide | Ipratropium Bromide | 96 | 42 |
| Meloxicam | Meloxicam | 96 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 28 |
| Azelastine Hcl | Azelastine Hcl | 90 | 43 |
| Famotidine | Famotidine | 90 | 32 |
| Ezetimibe | Ezetimibe | 89 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 33 |
| Synthroid | Levothyroxine Sodium | 87 | 23 |
| Eliquis | Apixaban | 81 | 22 |
| Methylprednisolone | Methylprednisolone | 81 | 57 |
| Lorazepam | Lorazepam | 80 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 25 |
| Farxiga | Dapagliflozin Propanediol | 74 | 21 |
| Atenolol | Atenolol | 73 | 17 |
| Estradiol | Estradiol | 72 | 28 |
| Naproxen | Naproxen | 68 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 50 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | 17 |
| Potassium Chloride | Potassium Chloride | 64 | 21 |
| Spironolactone | Spironolactone | 61 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 18 |
| Furosemide | Furosemide | 59 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 18 |
| Lovastatin | Lovastatin | 58 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 56 | 21 |
| Bupropion Xl | Bupropion Hcl | 55 | 19 |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 53 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 19 |
| Alendronate Sodium | Alendronate Sodium | 50 | 15 |
| Azithromycin | Azithromycin | 49 | 43 |
| Carvedilol | Carvedilol | 47 | 16 |
| Fenofibrate | Fenofibrate | 47 | 14 |
| Fluconazole | Fluconazole | 47 | 17 |
| Ibuprofen | Ibuprofen | 47 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 11 |
| Donepezil Hcl | Donepezil Hcl | 44 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 11 |
| Tramadol Hcl | Tramadol Hcl | 40 | 18 |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | 11 |
| Nystatin | Nystatin | 34 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | 13 |
| Buspirone Hcl | Buspirone Hcl | 32 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | 11 |
| Clonidine Hcl | Clonidine Hcl | 31 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | 11 |
| Finasteride | Finasteride | 29 | 11 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | 11 |
| Bupropion Hcl | Bupropion Hcl | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 25 | 11 |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 19 |
| Topiramate | Topiramate | 24 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 20 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | 11 |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 18 |
| Chlorzoxazone | Chlorzoxazone | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 14 |
| Clonazepam | Clonazepam | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Yuvafem | Estradiol | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 11 |
| Prednisone | Prednisone | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | 11 |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,546.49 · 57 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BOTOX, BREZTRI, COMIRNATY, Cologuard Collection Kit, DAXXIFY, FARXIGA, FREESTYLE LIBRE 3, GLYCATE, General - Pain Management, JARDIANCE, KEVEYIS, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, PREVNAR 20, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, TRELEGY ELLIPTA, Tymlos, UBRELVY, Veozah, WATCHMAN Access System, Wegovy, Xeomin, ZAVZPRET, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error